Ionis Pharmaceuticals Inc

NASDAQ:IONSUnited States

Oct 21, 2024

Show headlines and story abstract

• Sector Update: Health Care Stocks Lean Lower Premarket Monday, from 9:15AM ET on Monday Oct 21, 2024 by MT Newswires

  9:15AM ET on Monday Oct 21, 2024 by MT Newswires
  Companies Mentioned: IBB, IONS, OTRK, SNY, XLV, AZN
  09:15 AM EDT, 10/21/2024 (MT Newswires) -- Health care stocks were leaning lower premarket Monday with the Health Care Select Sector SPDR Fund (XLV) marginally declining and the iShares Biotechnology ETF (IBB) recently down 0.4%. Sanofi (SNY) said i...

• Ionis Pharmaceuticals Says Wainzua Recommended for Approval in European Union, from 3:48AM ET on Monday Oct 21, 2024 by MT Newswires

  3:48AM ET on Monday Oct 21, 2024 by MT Newswires
  Companies Mentioned: IONS, AZN
  03:48 AM EDT, 10/21/2024 (MT Newswires) -- Ionis Pharmaceuticals (IONS) said Monday the Committee for Medicinal Products for Human Use has recommended approval of the company and AstraZeneca's (AZN) Wainzua drug to treat hereditary transthyretin-med...

• WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, from 2:09AM ET on Monday Oct 21, 2024 by PR Newswire

  2:09AM ET on Monday Oct 21, 2024 by PR Newswire
  Companies Mentioned: IONS

  Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo

  Ionis Pharmaceuticals, Inc.(Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. If approved by the European Commission, WAINZUA will be the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.